PE-22-28
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Research-only mood and neuroplasticity peptide: PE-22-28 is pursued for subtle antidepressant-like support, hippocampal neurogenesis, and synaptogenesis, but the useful signal is still mouse-first and community-light rather than clinically proven.
The main stop sign is uncertainty: no human trials, no validated human route or dose, no chronic TREK-1 blockade safety record, and serotonergic stacking caution with SSRIs, MAOIs, 5-HTP, or similar agents.
Research-only mood and neuroplasticity peptide: PE-22-28 is pursued for subtle antidepressant-like support, hippocampal neurogenesis, and synaptogenesis, but the useful signal is still mouse-first and community-light rather than clinically proven.
The main risk is uncertainty, not an established organ-toxic profile: no human trials, no validated subcutaneous or intranasal bioavailability, mouse-IP dose extrapolation, lethargy at higher community doses, and additive serotonergic concern when stacked with SSRIs, MAOIs, 5-HTP, or similar agents.
Mechanistically distinct from SSRIs because it blocks TREK-1 potassium channels to increase neuronal excitability and downstream serotonergic/dopaminergic signaling rather than blocking reuptake. The payoff thesis is a different path for SSRI non-responders plus rapid mouse neurogenesis within 4 days, but that has not been translated into human efficacy.
Low-to-moderate community confidence. The best field report describes a gradual mood-floor lift, less intrusive negative thought patterning, and more motivation over days to weeks; it does not read like an acute antidepressant, stimulant, or dramatic mood switch. Null and weak-response risk remains high because route, dose, and responder profile are unsettled.
Intro
PE-22-28 is a synthetic 7-amino-acid heptapeptide (sequence GVSWGLR: Gly-Val-Ser-Trp-Gly-Leu-Arg) designed as an optimized analog of spadin, a naturally occurring peptide derived from positions 22–28 of the sortilin (neurotensin receptor 3) propeptide. Molecular weight: 773.89 Da; CAS: 1810959-12-5. It was developed by Djillani et al. in 2017 at IPMC-CNRS, Université Côte d'Azur, by screening serum degradation products of spadin to identify the minimal active fragment with improved potency and stability.
PE-22-28 selectively antagonizes TREK-1 (TWIK-related potassium channel 1), a two-pore domain background K+ channel expressed in the prefrontal cortex, hippocampus, and dorsal raphe nuclei — key mood-regulating and memory regions. TREK-1 knockout mice display a depression-resistant phenotype with increased 5-HT neurotransmission, establishing TREK-1 as a validated antidepressant target. PE-22-28 inhibits TREK-1 with an IC50 of 0.12 nM in hTREK-1/HEK cells — 300–500× more potent than the parent compound spadin (40–60 nM). Duration of action reaches 23 hours versus 7 hours for spadin.
All efficacy and safety data derives from a single 2017 mouse study. No human clinical trials have been conducted. Community protocols extrapolating to human subcutaneous and intranasal dosing have no published pharmacokinetic support.
Observed Effects
In mice at 3–4 mcg/kg IP: significantly reduced immobility time in the forced swimming test (FST) — the standard antidepressant behavioral screen.
In the novelty suppressed feeding test (NSF), a 4-day sub-chronic treatment significantly reduced latency to eat — an effect requiring 2–4 weeks with traditional antidepressants, achieved here in 4 days. Hippocampal neurogenesis (BrdU-positive new neurons) was measurable within 4 days of daily treatment; the G/A-PE 22-28 analog showed the most prominent neurogenic effect. On mouse cortical neurons, PE-22-28 enhanced synaptogenesis measured by increased PSD-95 expression — a marker of mature excitatory synaptic density. Possible post-stroke neuroprotective and cognitive recovery effects have been noted in preclinical stroke models with chronic treatment.
In community reports: gradual mood improvement described as 'bad thoughts subsiding' and 'more good days than bad' over days to weeks; increased motivation; possible mild memory improvement and sleep quality when used in neurogenesis stacks (confounded by multi-compound protocols). Effects are consistently described as subtle and cumulative, not acute or dramatic.
Field Reports
The evidence base for subjective community experience is narrow: one detailed 9-week first-person account, aggregated summaries of 40 reports, and scattered forum responses.
The most consistent pattern: effects are subtle and cumulative, not acute or dramatic. The detailed reporter described 'bad thoughts subsiding over the course of taking it' and 'motivation increased' — more background mood floor lifting than euphoria. He explicitly noted it 'is not a happy injection or something like tesofensine where you can pinpoint when it started kicking in.' Onset was 'a few days.' This aligns with the preclinical 4-day neurogenesis timeline but calibrates expectations well below what 'rapid antidepressant onset' might imply.
Tolerance signal: at 9 continuous weeks on 400 mcg/day, the same user escalated to 600 mcg because '400 mcg no longer works as well as the beginning.' This is the only documented tolerance case but supports the community recommendation to cycle with washouts.
Brain stack experiences: one user reported 'memory a little better and sleep is good' while on PE-22-28 with epithalon, pinealon, DSIP, and semax simultaneously — confounded attribution makes PE-22-28-specific claims impossible. A separate user described it as 'cognitive nootropic that puts the brakes on some inhibitors, essentially increasing excitability' after months of use with 'nothing crazy intense.'
Most commonly reported side effect across 40 aggregated community reports: lethargy at higher doses.
Community Consensus
PE-22-28 sits in the exploratory neuropeptide corner: enough mechanism to attract serious mood and brain-stack users, but not enough human signal to feel established.
The first detailed first-person report appeared recently, and by early 2026 the field layer was still sparse: a few documented discussions, 40 aggregated reports, and scattered protocol discussion, versus thousands of reports for semax or selank.
The main community thesis is SSRI-adjunct use for people who cannot increase an SSRI dose or want a mechanistically different mood lever without switching medications. The second thesis is neurogenesis/cognitive stacking, usually sequenced with cerebrolysin, dihexa, semax, or other neuroplasticity agents rather than treated as a standalone cognitive enhancer.
The community is conditionally interested rather than broadly bullish. Supporters like the TREK-1 mechanism, the mouse neurogenesis timeline, the low mcg-range cost, and the fact that it does not touch the HPG axis. Skeptics point to the same problem repeatedly: the practical protocols are extrapolated from mouse IP studies, intranasal and SubQ routes have no published PE-22-28 bioavailability bridge, and the best subjective report reads subtle rather than dramatic.
A higher-dose intranasal morning protocol became a common community reference point, but the article's evidence does not make that route or dose more validated than conservative SubQ titration. The stronger consensus is to treat PE-22-28 as an experimental adjunct or sequential brain-stack tool, not as a replacement for established depression care or a proven treatment-resistant-depression answer.
Cost efficiency is a real appeal because high potency can stretch material exposure, but cheap exposure does not solve the responder, route, or long-term-safety unknowns.
Risks & Monitoring
Preclinical profile: no negative cardiac or metabolic effects observed in animal studies — meaningful differentiation from some conventional antidepressants. No formal toxicology study exists for PE-22-28.
Community-reported adverse effects from 40 aggregated reports: lethargy at higher doses (the most consistently reported side effect). No severe adverse events documented in the available community data.
Mechanism-based theoretical risks: excessive serotonergic stimulation when stacking with SSRIs — both enhance 5-HT signaling via different mechanisms (additive serotonergic load); theoretical risk escalates at higher PE-22-28 doses (400–600 mcg) or with multiple serotonergic agents. TREK-1 has roles beyond mood regulation including pain modulation, ischemic neuroprotection, and temperature regulation — the effects of chronic TREK-1 blockade on these systems are entirely uncharacterized. Long-term safety data does not exist.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
General baseline screen before a research-only peptide. PE-22-28 does not have a known hematologic toxicity signal, so CBC is contextual rather than a safety gate.
General baseline liver and kidney screen. The article does not identify PE-22-28 hepatotoxicity or nephrotoxicity, so CMP helps document starting health rather than deciding whether ordinary use is safe.
Biochemical panels are not informative for PE-22-28's primary antidepressant endpoint. Standardized mood tracking (PHQ-9 or similar scale) at baseline and monthly provides the most meaningful signal for whether the compound is working
Avoid With
Do not combine PE-22-28 with the following. Sorted highest-severity first.
Why:MAOIs dramatically increase monoamine levels; combining with PE-22-28's serotonergic enhancement risks additive serotonergic toxicity. No PE-22-28-specific MAOI interaction data exists, but the mechanism-based risk is serious.
What to do:Treat as a hard avoid in the absence of data.
Why:Additive serotonergic load from multiple pathways. Concern escalates at higher PE-22-28 doses (400–600 mcg) or when combined with multiple serotonergic agents simultaneously.
What to do:At conservative doses (50–200 mcg), PE-22-28 is a mild serotonergic enhancer; risk increases with dose and serotonergic co-loading.
Protocols By Goal
For antidepressant or mood support as an SSRI adjunct: conservative SubQ titration (50→100 mcg/day over 8 weeks) is the most defensible approach.
If stacking with an SSRI, ensure your prescriber is informed and monitor for excessive serotonergic stimulation (agitation, insomnia, restlessness). Allow 1–2 weeks minimum before assessing response. Not appropriate as a replacement for established antidepressant therapy in moderate-to-severe depression — the community framing is as a 'speed bump' adjunct, not a standalone fix.
For neurogenesis and cognitive enhancement (brain stack): 100–200 mcg/day SubQ as part of a sequential, not simultaneous, neurogenesis protocol. Community preference: PE-22-28 course → washout → cerebrolysin → washout → dihexa, spaced to avoid theoretical 'neuron overactivation.' Semax or NA-Semax are noted as compatible additions for overlapping BDNF/neuroplasticity goals.
Dosing Details
All dosing is extrapolated from mouse intraperitoneal (IP) studies at 3–4 mcg/kg with no published pharmacokinetic bridging data for subcutaneous or intranasal routes in any species.
Conservative community titration (most documented pattern): once-daily SubQ use is typically described as starting in the low-mcg range and moving upward over several weeks only if tolerated. This should be read as reported practice, not an established safe or effective human protocol.
Intranasal community protocol: a higher once-daily intranasal dose became the most-cited reference pattern in community discussion. Intranasal use is theoretically motivated for direct CNS delivery but has zero published PE-22-28 bioavailability data.
Higher-dose SubQ (one documented user): continuous higher-dose use with escalation after tolerance appeared has been reported, including concurrent SSRI use. That case supports the tolerance/cycling warning more than it validates the dose.
Storage and cycle length are also extrapolated from general peptide practice. No compound-specific washout duration is established.
Stacks & Alternatives
PE-22-28 as a mood adjunct when SSRI dose cannot be increased or to enhance antidepressant response. Mechanistically complementary — different pathway to serotonergic enhancement. One documented first-person user ran this combination for 9 weeks.
Overlapping neurogenesis and neuroprotective effects; semax upregulates BDNF and has anxiolytic properties. Community uses this as a complementary 'brain stack' combination targeting similar hippocampal neuroplasticity pathways.
Used in extended brain stack protocols. Epithalon (anti-aging telomerase activator) and Pinealon (neuropeptide) are added alongside PE-22-28 in sequential or simultaneous neurogenesis protocols by advanced nootropic users.
Alternatives
Stack Cost
Low lab burden but moderate decision burden: PE-22-28 does not consume hormonal or organ-monitoring capacity, but it does occupy the CNS/mood lane and adds interaction uncertainty when combined with SSRIs or other serotonergic agents.
Serotonergic additive risk with SSRIs and other serotonergic agents; MAOI combination is a hard avoid. This is the primary pharmacological interaction concern.
Optional baseline CBC and CMP can document starting health, but no ongoing bloodwork is required from the article's known safety profile. Mood self-assessment (PHQ-9) is the most informative monitoring tool.
Mild serotonergic enhancement that could interact with other CNS-active compounds; lethargy at higher doses is the main observed effect.
- ·Avoid simultaneous use with MAOIs
- ·Use caution when combining with SSRIs or other serotonergic agents — monitor for agitation, insomnia, or restlessness
- ·No specific washout timing required relative to most other peptides
- ·No additional support compounds required — no HPG suppression, no hepatic or renal load identified
The article does not support an advanced-only safety label because PE-22-28 has no HPG suppression, virilization, organ-toxicity signal, or required lab gate in ordinary low-dose use. It is still intermediate/research-only because the human dose, route, efficacy, serotonergic interaction margin, and chronic TREK-1 blockade consequences are unresolved.
- ·Current MAOI use or multiple serotonergic agents
- ·Unstable depression, suicidality, mania risk, or recent psychiatric medication changes
- ·Pregnancy, lactation, or active conception attempts
- ·Using PE-22-28 as a replacement for established depression treatment
- ·Planning 400-600 mcg dosing without prescriber awareness when already on an SSRI
No taper, endocrine recovery, or PCT requirement is described. The practical off-ramp is stopping the compound, returning other CNS variables to baseline, and reassessing mood over the next 1-2 weeks.
- ·Return of baseline depressive symptoms if the compound was helping
- ·Difficulty attributing mood changes when SSRIs, semax, dihexa, cerebrolysin, or other neuroactive compounds are changed at the same time
- ·Unclear washout timing because human pharmacokinetics are not established
Use PE-22-28 only as an experimental adjunct framework, keep established care intact, and define a stop/escalation plan before starting.
Avoid MAOIs, avoid stacking multiple serotonergic agents, start conservatively, and stop/escalate clinically if stimulation symptoms appear.
Treat all human dosing as speculative, prefer conservative titration, and separate dose changes from other CNS-active stack changes.
The article's main interaction concern is additive serotonergic load. These contexts make agitation, insomnia, restlessness, and other stimulation signals more consequential.
PE-22-28 is being used for mood endpoints without human clinical data. Unstable psychiatric contexts turn a subtle experimental signal into a higher-consequence trial.
There is no reproductive safety data, and womenConsiderations already treats pregnancy and lactation as avoid contexts.
Practical Setup
PE-22-28 is not a starter peptide for mood support. It is a novel, preclinical-only compound with no human clinical data and no established safe or effective dose.
If exploring neuropeptides for mood or cognitive support, more characterized options (selank, semax) offer a better-understood starting point.
For research-only users proceeding: conservative SubQ titration (50 mcg → 100 mcg/day) is the most defensible protocol given the compound's high potency. Higher doses (400–600 mcg) have been used but with unknown safety margin. Route uncertainty is significant — intranasal delivery is pharmacologically motivated but entirely unvalidated; SubQ has slightly more precedent in protocol guides.
Cycling: 8–12 weeks on with 4–8 week washout is reasonable given the one observed tolerance signal at continuous 9-week use. No compound-specific guidance exists.
Drug interaction flags: avoid MAOIs. Use caution with SSRIs (additive serotonergic effect), high-dose 5-HTP, and multiple simultaneous serotonergic agents. TREK-1 is involved in pain modulation — possible interactions with opioids or gabapentinoids are speculative.
Monitoring: optional baseline CBC and CMP can document general health, but they are not PE-22-28-specific safety gates. The most useful monitoring is a standardized mood self-assessment (PHQ-9 or equivalent) at baseline and monthly because biochemical labs do not measure the compound's primary endpoint. If stacking with an SSRI, ensure your prescriber is aware of the combination.
Mechanism Deep Dive
PE-22-28 selectively blocks TREK-1 (TWIK-related potassium channel 1) — a two-pore domain background K+ channel maintaining neuronal hyperpolarization via K+ efflux.
Binding occurs at sub-nanomolar affinity (IC50 0.12 nM). By blocking K+ outflow, PE-22-28 increases neuronal excitability in serotonergic and dopaminergic circuits including the prefrontal cortex, hippocampus, and dorsal raphe nuclei.
TREK-1 knockout mice display a depression-resistant phenotype with increased 5-HT neurotransmission — the genetic validation of this target. PE-22-28 pharmacologically mimics the knockout phenotype.
Downstream signaling cascade: increased neuronal excitability → enhanced 5-HT and dopamine release → CREB phosphorylation → BDNF upregulation → mTOR pathway activation → hippocampal neurogenesis (measurable within 4 days) → synaptogenesis (PSD-95 upregulation).
Comparison to SSRIs: SSRIs block SERT to prevent serotonin reuptake, increasing synaptic 5-HT concentration. PE-22-28 increases neuronal excitability of serotonergic neurons, increasing 5-HT release. The two mechanisms can be additive (supporting adjunct rationale) but may also produce excessive serotonergic stimulation at high combined doses.
TREK-1 has roles beyond mood regulation: pain modulation, ischemic neuroprotection, and temperature regulation. Chronic blockade effects on these systems are entirely uncharacterized — an important unknown for long-term use.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
PE-22-28 inhibits TREK-1 with IC50 of 0.12 nM (vs 40-60 nM for spadin)
Strong mechanistic finding. In vitro IC50 does not predict human effective dose or appropriate dosing.
PE-22-28 reduces immobility in forced swimming test in mice
Standard antidepressant behavioral screen. IP administration only; no equivalence to human SubQ or intranasal use established.
4-day sub-chronic treatment induces hippocampal neurogenesis; NSF latency significantly reduced
Key translational claim for rapid onset neurogenesis. G/A-PE 22-28 analog showed most prominent neurogenic effect. Human equivalence unestablished.
Duration of action 23 hours vs 7 hours for spadin after single dose
Supports once-daily dosing rationale. IP duration does not predict SubQ or intranasal duration in humans.
9 weeks of 400-600 mcg/day SubQ use as SSRI adjunct produced gradual mood improvement with tolerance at week 9
Only detailed first-person report available. Single case; not generalizable. Simultaneous SSRI confounds attribution.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.